Skip to content

Oncolytic virus-based immunotherapies for hepatocellular carcinoma

Document Type
Publications · Review Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q2Scopus Q2
Journal
MEDIATORS OF INFLAMMATION2017 · 2017
Citation
Web of Science 40Scopus 44
FWCI (Scopus)
0.42
JCR IF
JCR 2016 3.232
ISSN
0962-9351

Authors

  1. Yoo, So YoungFirst authorCorresponding authorBIO-IT Foundry Technology Institute, Pusan National University, Busan, South Korea
  2. Badrinath, NarayanasamyBIO-IT Foundry Technology Institute, Pusan National University, Busan, South Korea
  3. Woo, Hyung-youngDepartment of Internal Medicine, College of Medicine, Pusan National University, Medical Research Institute, Yangsan, South Korea
  4. Heo, JeongDepartment of Internal Medicine, College of Medicine, Pusan National University, Medical Research Institute, Yangsan, South Korea

Abstract

Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.

Identifiers

Scopus EID
2-s2.0-85018993312
WoS UID
000399497700001